Colgate-Palmolive

Colgate-Palmolive is the textbook defensive name nobody talks about — and that is exactly why it keeps compounding. In 2026, the company is on the cusp of its 63rd consecutive year of dividend increases, putting it inside the rarefied Dividend King club alongside Procter & Gamble and Johnson & Johnson. Yet the real story for 2026 is not toothpaste — it is Hill's Pet Nutrition. The premium pet-food segment now contributes roughly 21% of total revenue and is growing organic revenue near 8% annually, more than double the pace of the legacy oral-care business. Management has quietly built Hill's into a $4.5B high-margin franchise that competes with Nestlé Purina and Mars in the prescription and science-diet niche. The pet-humanization trend (owners spending more on food than on themselves during downturns) is doing the heavy lifting while Oral, Personal & Home Care delivers single-digit organic growth in emerging markets. Colgate trades at a forward P/E around 24× — a premium to the staples median because the cash conversion is near 100% and the buyback program just authorized another $5B.

Berkshire Hathaway does not hold Colgate, but Ken Fisher's Fisher Asset Management has held a consistent position above 1.4M shares through 2025–2026 13F filings. The reason institutional capital stays sticky here is that Colgate's emerging-market footprint (43% of revenue from Latin America, India, China, Africa) makes it the cleanest USD play on rising middle-class consumption outside the US. Defensive funds favor Colgate over P&G specifically because of Hill's — pet food is the rare staples sub-segment with structural pricing power. The recent dividend hike to an annualized $2.16/share signals management confidence ahead of the 2026 Brazil and Mexico margin recovery (FX-neutral pricing was up 9.2% in Q1/2026). Smart money tends to size positions on weakness around $80–$82 — that level has been the long-run 20-year support relative to the S&P 500 staples sector.

Forward P/E of 24.1× — above the 5-year average of 23.4× and the staples-median of 21×. EV/EBITDA of 17.2× compares with Procter & Gamble at 18.5× and Unilever at 13.9×. The premium versus Unilever is justified by superior gross margin (60%+ vs Unilever's 44%) and a far higher dividend-growth streak. Discount versus P&G reflects smaller scale and less innovation cadence. Free-cash-flow yield of 4.6% is healthy given the ~2.3% dividend yield, implying ~50% of FCF returned via buybacks. Bull case: Hill's segment re-rates to a separate ~25× pet-premium multiple — fair value $98. Bear case: GLP-1 + private-label squeeze takes the multiple to 20× — fair value $76.

1. July 25, 2026: Q2/2026 earnings call — Hill's segment organic-growth read; consensus is +7.5% and any beat above 9% would be a multiple-expansion event.
2. October 24, 2026: Q3/2026 earnings + FY guidance refresh — Latin America FX-neutral pricing trajectory and the next dividend hike announcement (64th consecutive year).
3. January 30, 2027: Q4/2026 + full-year — Hill's capacity-expansion update; new Tonganoxie, Kansas plant comes online and should add ~8% to annual production capacity.

Colgate is the position you build slowly during equity-market panics. You will not get rich owning it, but you will not get hurt either. The Hill's pet-food story is the underappreciated alpha — most analysts still model it as a stable contributor when it is actually the growth engine. I would not chase above $92, but anywhere below $84 the risk-reward becomes asymmetric: limited downside thanks to the dividend floor, mid-single-digit total-return upside annually for the next 5 years. This is a sleep-well-at-night holding in a Dividend Aristocrat allocation, not a tactical trade. Size it like a bond proxy with equity upside.